<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Biocon</title>
	<atom:link href="http://www.tapanray.in/tag/biocon/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Improving Patient Access To Biosimilar Drugs: Two Key Barriers</title>
		<link>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=improving-patient-access-to-biosimilar-drugs-two-key-barriers</link>
		<comments>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/#comments</comments>
		<pubDate>Mon, 31 Jul 2017 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8334</guid>
		<description><![CDATA[Novel biologic medicines have unlocked a new frontier offering more effective treatment for a host of chronic and life-threatening diseases, such as varieties of cancer, rheumatoid arthritis and diabetes, to name just a few. However, these drugs being hugely expensive, &#8230; <a href="http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Emerging Yo-Yo Syndrome With Biosimilar Drugs</title>
		<link>http://www.tapanray.in/an-emerging-yo-yo-syndrome-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-emerging-yo-yo-syndrome-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/an-emerging-yo-yo-syndrome-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 18 Jul 2016 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Adalimumab]]></category>
		<category><![CDATA[Affordable Care Act]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[hurdle]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scandalizing]]></category>
		<category><![CDATA[Shield]]></category>
		<category><![CDATA[Syndrome]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yo-Yo]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7727</guid>
		<description><![CDATA[Competition from Biosimilar drugs poses a threat of a combined revenue loss of estimated US$ 110 billion of those pharma players who are still enjoying market monopoly with patented biologic brands. This is expected to surely happen, in the long &#8230; <a href="http://www.tapanray.in/an-emerging-yo-yo-syndrome-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-emerging-yo-yo-syndrome-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: First Indian Foot Print In An Uncharted Frontier</title>
		<link>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/#comments</comments>
		<pubDate>Mon, 04 Apr 2016 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insulin]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[label]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[lantus XR]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[non-proprietory]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[pen]]></category>
		<category><![CDATA[pre-filled]]></category>
		<category><![CDATA[prescriber]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toujeo]]></category>
		<category><![CDATA[uncharted]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7578</guid>
		<description><![CDATA[A homegrown Indian biologic manufacturer is now about to leave behind its first foot-print, with a ‘made in India’ biosimilar drug, in one of the largest pharma market of the world. This was indeed an uncharted frontier, and a dream &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-first-indian-foot-print-in-an-uncharted-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alarming Incidence of Cancer: Fragile Infrastructure: Escalating Drug Prices</title>
		<link>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices</link>
		<comments>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/#comments</comments>
		<pubDate>Mon, 28 Jul 2014 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[alarming]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[Astellas Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[evaluate]]></category>
		<category><![CDATA[fact]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance Life Science]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sheet]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5672</guid>
		<description><![CDATA[According to the &#8216;Fact-Sheet 2014&#8242; of the World Health Organization (WHO), cancer cases would rise from 14 million in 2012 to 22 million within the next two decades. It is, therefore, no wonder that cancers figured among the leading causes &#8230; <a href="http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Moving Up The Generic Pharma Value Chain</title>
		<link>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=moving-up-the-generic-pharma-value-chain</link>
		<comments>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/#comments</comments>
		<pubDate>Mon, 30 Jun 2014 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[BIPP]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fondaparinux]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlobaData]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moving]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Ohm]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SBIRI]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Valcyte]]></category>
		<category><![CDATA[valsartan]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5565</guid>
		<description><![CDATA[June 2014 underscores a significant development for the generic drug exporters of India. Much-delayed and highly expected launch of generic Diovan (Valsartan) is now on its way, as Ranbaxy has reportedly received US-FDA approval to launch the first generic version of this blood pressure drug &#8230; <a href="http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>RHDS: A Simmering Promise in Despondency</title>
		<link>http://www.tapanray.in/rhds-a-simmering-promise-in-despondency/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rhds-a-simmering-promise-in-despondency</link>
		<comments>http://www.tapanray.in/rhds-a-simmering-promise-in-despondency/#comments</comments>
		<pubDate>Mon, 05 May 2014 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[availabity]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[despondency]]></category>
		<category><![CDATA[e-healthcare]]></category>
		<category><![CDATA[Eric]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[ICT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ISRO]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RHDA]]></category>
		<category><![CDATA[Simmering]]></category>
		<category><![CDATA[smartphones]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Ted]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[Topol]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5206</guid>
		<description><![CDATA[Eric Topol, a leading cardiologist who has embraced the study of genomics and the latest advances in technology to treat chronic disease says, “We&#8217;ll soon use our smartphones to monitor our vital signs and chronic conditions in future.” By clicking &#8230; <a href="http://www.tapanray.in/rhds-a-simmering-promise-in-despondency/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rhds-a-simmering-promise-in-despondency/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Just Born A Pharma Goliath: Would India Be Impacted?</title>
		<link>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=just-born-a-pharma-goliath-would-india-be-impacted</link>
		<comments>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/#comments</comments>
		<pubDate>Mon, 03 Mar 2014 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actavis]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chilcott]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Goliath]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[MerckSerono]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Seksharia]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[super]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[Watson]]></category>
		<category><![CDATA[Zentiva]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5030</guid>
		<description><![CDATA[Just born a potential pharma Goliath, as Actavis &#8211; the Dublin-based one of the largest global generic drug makers, in its biggest ever purchase, acquires New York based R&#38;D based pharma major &#8211; Forest Laboratories, for a whopping US$ 25 billion. &#8230; <a href="http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Herceptin Biosimilars’ Seriously Questioned</title>
		<link>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=herceptin-biosimilars-seriously-questioned</link>
		<comments>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/#comments</comments>
		<pubDate>Fri, 07 Feb 2014 11:17:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[canmab]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CTRI]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hertaz]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[questioned]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[wife]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4969</guid>
		<description><![CDATA[The news struck as an anticlimax, close on the heels of high decibel product launch of ‘Herceptin Biosimilars’ in India, being hyped as the first in the world, bringing much needed relief to many diagnosed breast cancer patients for their &#8230; <a href="http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Herceptin Biosimilar Expands Drug Access to Breast Cancer Patients in India</title>
		<link>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india</link>
		<comments>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/#comments</comments>
		<pubDate>Fri, 24 Jan 2014 13:37:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[canmab]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[herclon]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MabThera]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4908</guid>
		<description><![CDATA[Come February 2014, much to the relief of more than 145,000 patients diagnosed with breast cancer in India, Herceptin of Roche, a critical drug for the treatment of the dreaded disease, will face competition, for the first time, from a &#8230; <a href="http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Horizon: Cloud, Rainbow And Smear</title>
		<link>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-horizon-cloud-rainbow-and-smear</link>
		<comments>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/#comments</comments>
		<pubDate>Mon, 09 Dec 2013 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cloudy]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[monster]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sky]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[taint]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[total]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[UKMHRA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VUCA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4400</guid>
		<description><![CDATA[Some recent papers contemplated that the patent cliff for blockbuster drugs has already reached the zenith and early signs of recovery should be visible from 2013 onwards. However, from analysis of the currently available data, contrary to the above belief, I reckon, the downtrend &#8230; <a href="http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
